Canopy Growth (CGC) Interest & Investment Income (2019 - 2025)
Canopy Growth (CGC) reported Interest & Investment Income of $4.4 million for Q4 2025, up 216.52% on a YoY basis from $1.4 million in Q4 2024, and up 206.3% sequentially from $1.4 million in Q3 2025.
Canopy Growth (CGC) Interest & Investment Income (2019 - 2025) Analysis & Trends
Canopy Growth (CGC) has 7 years of Interest & Investment Income data on file, last reported at $4.4 million in Q4 2025.
- For the quarter ending Q4 2025, Interest & Investment Income rose 216.52% year-over-year to $4.4 million; the trailing twelve-month figure through Dec 2025 stood at $8.0 million (up 23.86% YoY), and the FY2026 full-year result was $7.3 million, up 18.66% from the prior year.
- Interest & Investment Income grew to $4.4 million in Q4 2025, from $1.4 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $6.2 million in Q1 2023 to a low of -$296842.8 in Q1 2022.
- A 5-year average of $2.6 million and a median of $1.9 million in 2023 frame the typical range for Interest & Investment Income.
- Across the five-year window, Interest & Investment Income slumped 116.41% in 2022 and surged 2183.21% in 2023, its largest moves.
- Tracing CGC's Interest & Investment Income over 5 years: stood at $1.2 million in 2021, then soared by 315.55% to $5.2 million in 2022, then plunged by 63.95% to $1.9 million in 2023, then slipped by 25.76% to $1.4 million in 2024, then soared by 216.52% to $4.4 million in 2025.
- Business Quant data shows CGC's Interest & Investment Income at $4.4 million in Q4 2025, $1.4 million in Q3 2025, and $762850.1 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Canopy Growth | 276.52 Mn | 10.60 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.40 Mn |
| Sep 30, 2025 | 1.44 Mn |
| Jun 30, 2025 | 762,850.11 |
| Dec 31, 2024 | 1.39 Mn |
| Sep 30, 2024 | 1.77 Mn |
| Jun 30, 2024 | 1.50 Mn |
| Mar 31, 2024 | 1.78 Mn |
| Dec 31, 2023 | 1.87 Mn |
| Sep 30, 2023 | 2.58 Mn |
| Jun 30, 2023 | 5.83 Mn |
| Mar 31, 2023 | 6.18 Mn |
| Dec 31, 2022 | 5.19 Mn |
| Sep 30, 2022 | 3.78 Mn |
| Jun 30, 2022 | 3.10 Mn |
| Mar 31, 2022 | -296,842.75 |
| Dec 31, 2021 | 1.25 Mn |
| Sep 30, 2021 | 2.19 Mn |
| Jun 30, 2021 | 2.15 Mn |
| Mar 31, 2021 | 1.81 Mn |
| Dec 31, 2020 | 5.61 Mn |